WallStSmart

Merck & Company Inc (MRK)vsRapid Micro Biosystems Inc (RPID)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 191175% more annual revenue ($65.77B vs $34.38M). MRK leads profitability with a 13.6% profit margin vs -145.8%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

RPID

Avoid

29

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -10.25
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for RPID.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

RPID0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RPID4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$99.14M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.163/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : RPID

Revenue growth of 11.1% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : RPID

The primary concerns for RPID are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while RPID is a turnaround play — different risk/reward profiles.

RPID carries more volatility with a beta of 1.46 — expect wider price swings.

RPID is growing revenue faster at 11.1% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Rapid Micro Biosystems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Rapid Micro Biosystems Inc (RPID) is an innovative biotechnology company focused on revolutionizing microbiological quality control processes within the pharmaceutical and biotechnology industries. Utilizing state-of-the-art automated growth-based microbial detection technologies, RPID significantly improves the accuracy and efficiency of microbial testing, which is vital for adhering to stringent regulatory standards. As demand for rapid and reliable quality assurance solutions continues to grow, Rapid Micro is well-positioned to drive advancements in testing methodologies that are essential for maintaining product safety and excellence in highly regulated environments.

Visit Website →

Want to dig deeper into these stocks?